Mifepristone Used to Treat Patients With Non-psychotic Major Depressive Disorder Referred for Bilateral Electroconvulsive Therapy (ECT)

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00285818
First received: January 31, 2006
Last updated: September 15, 2010
Last verified: September 2010

January 31, 2006
September 15, 2010
January 2003
January 2009   (final data collection date for primary outcome measure)
Hamilton Depression Rating Scale [ Time Frame: Screening to Final Visit ] [ Designated as safety issue: No ]
Does mifepristone increase the clinical effectiveness of ECT as measured by the number of required ECT treatments?
Complete list of historical versions of study NCT00285818 on ClinicalTrials.gov Archive Site
  • Neuropsychiatric Assessments [ Time Frame: Time 1 versus post ECT time points ] [ Designated as safety issue: No ]
  • Does mifepristone act as a protective agent to cognitive function as measured by the difference in neuropsychiatric assessments between placebo and mifepristone groups [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
Does mifepristone act as a protective agent to cognitive function as measured by the difference in neuropsychiatric assessments between placebo and mifepristone groups?
Not Provided
Not Provided
 
Mifepristone Used to Treat Patients With Non-psychotic Major Depressive Disorder Referred for Bilateral Electroconvulsive Therapy (ECT)
A Double-blind, Placebo-controlled Study of Mifepristone in Patients With Non-psychotic Major Depressive Disorder Referred for Bilateral Electroconvulsive Therapy (ECT)

The purpose of this study is to see whether the medication mifepristone is an effective and tolerable treatment for increasing the clinical effectiveness of electroconvulsive therapy (ECT) and protecting cognitive function during ECT. Both Mifepristone and ECT appear to normalize hyperfunctioning of the hypothalmic-pituitary-adrenal (HPA) axis, which has been found among patients with major depression referred for ECT. The combination of these two treatments in major depression may lead to a more rapid clinical response than ECT alone. Additionally, there appears to be a connection between pre-ECT higher cortisol levels due to HPA axis hyperfunctioning and post-ECT cognitive impairment. Administration of mifepristone prior to and during ECT treatment may reduce cortisol levels and reduce the incidence of cognitive impairment observed after ECT.

Patients referred to the Stanford ECT Service who provide informed consent for this study will be screened for eligibility.

Day -4 to 0: Screening (visit 1) will occur three to six days prior to the first ECT treatment. Screening procedures will include: Psychiatric interviews and ratings (including MINI, Hamilton Depression Rating Scale and Clinician's Global Impression) and review/retrieval of results of pre-ECT physical exam, ECG, chest x-ray, laboratory evaluations (including comprehensive metabolic panel, comprehensive blood count, and urine toxicology), and vital signs from the subject's medical record. A urine pregnancy test will be included for females of childbearing potential. Concomitant medications and pre-existing health issues will be recorded. Subjects who are deemed eligible for this study will then undergo a battery of neuropsychiatric assessments and will be admitted to GCRC for collection of blood samples to measure adrenocorticotropin (ACTH) and cortisol levels. These samples will be collected hourly beginning at 1pm and ending at 4pm.

Day 1: Subjects will be randomized 1:1 to receive either mifepristone 600mg or placebo each day at bedtime beginning two days prior to the first ECT treatment. Subjects will be administered study medication on Day 1 through Day 8.

Day 3: Subjects will be interviewed with the Hamilton Depression Rating Scale and Clinician's Global Impression before their first ECT treatment.

Day 11: (visit 2) assessments will include psychiatric ratings (including Hamilton Depression Rating Scale and Clinician's Global Impression) and a battery of neuropsychiatric assessments. Adverse events and concomitant medications will be reviewed and recorded. Subjects will be admitted to the GCRC for collection of blood samples to measure ACTH and cortisol levels. Samples will be collected hourly beginning at 1pm and ending at 4pm.

Day 18: (visit 3) assessments will include psychiatric ratings (including Hamilton Depression Rating Scale and Clinician's Global Impression). Adverse events and concomitant medications will be reviewed and recorded. Clinical laboratory assessments will be completed (including a urine pregnancy test for females, comprehensive metabolic panel, comprehensive blood count, urine toxicology, and ECG.) Final visit: (visit 4) will occur 24-72 hours after the last ECT treatment. Assessments will include psychiatric ratings (including Hamilton Depression Rating Scale and Clinician's Global Impression) and a battery of neuropsychiatric assessments. Adverse events and concomitant medications will be reviewed and recorded. A urine pregnancy test will be completed for females.

In addition to the ECT treatment consent, the following materials will be collected from the participant's medical record for every ECT treatment: ECT treatment orders, ECT procedure note and the results of each pre-ECT Montgomery-Asberg Depression Rating Scale (MADRS). ECT treatments at Stanford's ECT Service run every Monday, Wednesday and Friday.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Depression
Drug: Mifepristone
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
April 2009
January 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:To be considered for participation in the study, subject must meet all of the following criteria:

  1. Meets DSM-IV criteria for Major Depressive Episode without psychotic features.
  2. 18-75 years of age and able to provide legal consent.
  3. Referred to Stanford ECT service by treating physician for bilateral electroconvulsive therapy with inpatient hospitalization.
  4. Completed process for consenting to the clinical use of ECT according to California State law.
  5. Females of childbearing potential must be using a double-barrier method of contraception during the study and for 30 days after the study (modified 6-2003)

Exclusion Criteria:Subjects will be excluded from participation if they meet any of the following criteria:

  1. Treatment with ECT in the 6 months prior to screening.
  2. Meets criteria for drug or alcohol abuse or dependence in the 6 months prior to screening.
  3. Use of alcohol or illegal drugs within seven days of randomization or during study.
  4. Presence of unstable or untreated cardiovascular disease, hypertension, or endocrine disorder as determined by investigator.
  5. Use of antipsychotic, antidepressant, or other prescription medications unless dose is stable for at least 7 days prior to randomization.
  6. Use of any investigational treatment within 30 days of randomization.
  7. Current pregnancy.
  8. Current lactation.
  9. Previous allergic reaction to mifepristone or drugs of similar chemical structure. (added 6-2003)
  10. Use of any oral contraceptives or other drugs that may result in adverse drug-mifepristone interaction effects. A 30-day wash out period for oral contraceptives is required before mifepristone begins.
Both
18 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00285818
2HSE450, 12062
Not Provided
Hugh Brent Solvason, Stanford University School of Medicine
Stanford University
National Institutes of Health (NIH)
Principal Investigator: Hugh Brent Solvason Stanford University
Stanford University
September 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP